Tag: non-Hodgkin lymphoma
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
Novel ADC Technology Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies...
Lymphomas, a group of cancers that originate in the lymphatic system, include both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Non-Hodgkin lymphoma, which is...
Phase II Trial of Denintuzumab Mafodotin Combination Therapy in Relapsed or...
A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...
Phase II Clinical Trial of Brentuximab Vedotin Combination Therapy in...
Based on encouraging data in patients with CD30-expressing relapsed or refractory diffuse large B-cell lymphoma or DLBCL, the most common type of aggressive non-Hodgkin Lymphoma...
First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...
Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...
